Our in vitro studies further demonstrate that GH promotes therapy resistance and metastatic phenotypes in NSCLC by upregulating ABC transporters, inducing EMT, and modulating ECM remodeling. Here, ABCG2 is linked to non-small cell lung carcinoma.